CALIXAR’s technology empowers clients to generate antibodies / nanobodies / synthetic antibodies with more dependable efficiency when producing new antigens for developing innovative antibodies.
CALIXAR creates high-quality native antigens to facilitate antibody and nanobody discovery. Our antigens are compatible with immunizations, phage displays, yeast displays, synthetic displays.
In addition, our technology also yields a more reliable understanding of antibody/antigen recognition and facilitates the discovery of the mechanism of action.
CALIXAR’s Antibody Discovery technology is ideal for bio drug (Biologics) /antibody discovery scientists (Pharma, biotechs, academics) that are involved in antibody development and characterization.
CALIXAR’s technology maintains the structural and functional integrities of the antigens allowing for the accurate development of conformational antibodies / nanobodies with therapeutic potential. This approach is used in antibody/antigen interaction studies
Traditionally, antibody discovery was performed with low-quality antigens (peptide, extracellulaire domain , DNA/Cell immunization) which can be of low immunogenicity, inaccurate conformation) selectively/specificity.
CALIXAR uses patented technology and customizes each antibody/nanobody development project.
The CALIXAR® platform applies patented technologies solely available for clients under particular contracts (license, co-development, and service).
You can leverage CALIXAR’s proprietary technology as well as other best-in-class membrane protein technology not available anywhere else on the market.